Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03379675 · ClinicalTrials.gov registry record · Phase 2
A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT03379675 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 72 participants.
The verdict
NCT03379675, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The purpose of this study is to explore the antiviral effect of JNJ-53718678 at 2 dose levels (80 milligrams \[mg\] and 500 mg) once daily for 7 days in adults with Respiratory Syncytial Virus (RSV) infection, as measured by RSV viral load in nasal secretions by quantitative reverse transcription polymerase chain reaction (qRT-PCR) assay.
Interventions
- DRUG Placebo
- DRUG JNJ-53718678 500 mg
- DRUG JNJ-53718678 80 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2019-12-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03379675
The ClinicalTrials.gov registry entry for NCT03379675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03379675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03379675 about?
NCT03379675 is a clinical study titled "A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus". The purpose of this study is to explore the antiviral effect of JNJ-53718678 at 2 dose levels (80 milligrams \[mg\] and 500 mg) once daily for 7 days in adults with Respiratory Syncytial Virus (RSV) infection, as measured by RSV viral load in nasal secretions by quantitative reverse transcription po...
What is the current status of trial NCT03379675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2018-02-06. Estimated completion is 2019-12-26.
What interventions are being tested in trial NCT03379675?
The interventions under investigation include: Placebo (DRUG), JNJ-53718678 500 mg (DRUG), JNJ-53718678 80 mg (DRUG).
Who is sponsoring clinical trial NCT03379675?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.